DFPH Share Price | The Oncology Institute, Inc. Stock Analysis & Recommendation

Q: Is The Oncology Institute, Inc. overvalued or undervalued?

As of 10 May 2023, the valuation grade for The Oncology Institute, Inc. has moved from attractive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, particularly given its significant negative ratios, including a Price to Book Value of 48.83 and an EV to EBITDA of -6.34. Additionally, its ROCE stands at a troubling -113.07%, reflecting severe inefficiencies in capital utilization.In comparison to its peers, The Oncology Institute's EV to EBITDA ratio of -8.88 is considerably worse than Nutex Health, Inc., which has a very attractive EV to EBITDA of 1.88, highlighting a stark contrast in operational performance. Other risky peers like LifeMD, Inc. and The Joint Corp. also exhibit negative EV to EBITDA ratios, but none approach the extreme levels seen with The Oncology Institute. Despite a remarkable year-to-date stock return of 948.54%, which significantly outperformed the S&P 500's 12.22%, the long-term outlook remains concerning, especially given the negative returns over the past three and five years.

Q: Is The Oncology Institute, Inc. technically bullish or bearish?

As of 25 August 2025, the technical trend for The Oncology Institute, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating mild bullishness, while the weekly MACD and KST show mildly bearish signals. The monthly MACD and KST are bullish, and Bollinger Bands reflect a bullish to mildly bullish trend across time frames. However, the weekly RSI shows no signal and the monthly RSI is bearish, indicating some weakness.In terms of performance, the company has significantly outperformed the S&P 500 year-to-date with a return of 948.54% compared to the S&P 500's 12.22%, but it has underperformed over the longer 3-year and 5-year periods.

Q: What does The Oncology Institute, Inc. do?

Overview: The Oncology Institute, Inc. is a company in the Pharmaceuticals & Biotechnology industry, focusing on healthcare-related business combinations.Financial Snapshot: Most recent Net Sales: 104 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -16 Million (Quarterly Results - Mar 2025) Market cap: USD 215.08 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 8.08 Return on Equity: -1,040.97% Price to Book: 42.43Contact Details: Address: 780 Third Avenue, NEW YORK NY: 10017 Tel: 1 212 5511600 Fax: 1 302 6365454

Q: Should I buy, sell or hold The Oncology Institute, Inc.?

Based on the current financial situation of The Oncology Institute, Inc., it would be advisable to consider selling your shares. The company is experiencing significant challenges, including a negative return on capital employed (ROCE) of -227.77% and an exceptionally high debt-to-equity ratio of 1,234.31%. Additionally, the company has a negative EBITDA, indicating that it is not generating earnings before interest, taxes, depreciation, and amortization.While the stock has not generated any returns over the past year, its profits have only increased by 7%, which may not be sufficient to justify the risks associated with holding the stock. Given these factors, it seems prudent to reevaluate your investment in The Oncology Institute, Inc. and consider selling.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

446.82 k

Shareholding (Mar 2026)

FII

3.82%

Held by 23 FIIs

DII

92.78%

Held by 21 DIIs

Promoter

3.40%

Is The Oncology Institute, Inc. overvalued or undervalued?

20-Sep-2025

As of May 10, 2023, The Oncology Institute, Inc. has shifted from an attractive to a risky valuation grade due to severe inefficiencies reflected in its negative financial ratios, indicating it is overvalued despite a significant year-to-date stock return of 948.54%.

View full answer

Is The Oncology Institute, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, The Oncology Institute, Inc. shows a mildly bullish trend with strong year-to-date performance of 948.54%, despite mixed signals from technical indicators and underperformance over the past 3- and 5-year periods.

View full answer

How big is The Oncology Institute, Inc.?

22-Jun-2025

As of Jun 18, The Oncology Institute, Inc. has a market capitalization of 215.08 million, with net sales of 403.16 million and a net profit of -52.80 million over the last four quarters. Shareholder's funds are reported at 3.59 million, and total assets amount to 181.91 million.

View full answer

What does The Oncology Institute, Inc. do?

22-Jun-2025

The Oncology Institute, Inc. operates in the Pharmaceuticals & Biotechnology sector, focusing on healthcare-related business combinations, with recent net sales of $104 million and a net loss of $16 million. The company has a market cap of $215.08 million and key metrics indicating significant financial challenges.

View full answer

Should I buy, sell or hold The Oncology Institute, Inc.?

22-Jun-2025

Compare The Oncology Institute, Inc. with Similar Stocks

The Joint Corp. (United States)Biodesix, Inc.Nutex Health, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -302.91% of over the last 5 years
Low ability to service debt as the company has a high Debt to EBITDA ratio of -2.90 times

With a growth in Net Sales of 41.22%, the company declared Very Positive results in Mar 26

Risky -

High Institutional Holdings at 52.88%

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 293 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-3.25

Return on Equity

240.52%

Price to Book

-18.61

Revenue and Profits:

Net Sales:

147 Million

(Quarterly Results - Mar 2026)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

56.7%

6 Months

48.82%

1 Year

119.65%

2 Years

1040.59%

3 Years

798.21%

4 Years

-20.54%

5 Years

-49.7%

The Oncology Institute, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

247.09%

EBIT Growth (5y)

-302.91%

EBIT to Interest (avg)

-18.48

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

8.08

Sales to Capital Employed (avg)

4.09

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

52.88%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-18.61

EV to EBIT

-9.52

EV to EBITDA

-11.79

EV to Capital Employed

9.73

EV to Sales

0.68

PEG Ratio

Dividend Yield

ROCE (Latest)

-102.20%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 20 Schemes (16.25%)

Foreign Institutions

Held by 23 Foreign Institutions (3.82%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 41.19% vs 10.24% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 86.96% vs 1.23% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "147.40",
          "val2": "104.40",
          "chgp": "41.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.90",
          "val2": "-8.10",
          "chgp": "39.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "5.60",
          "chgp": "-66.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "5.20",
          "val2": "-3.40",
          "chgp": "252.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.10",
          "val2": "-16.10",
          "chgp": "86.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-44.20%",
          "val2": "-94.90%",
          "chgp": "5.07%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 27.78% vs 21.34% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 5.09% vs 21.94% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "502.70",
          "val2": "393.40",
          "chgp": "27.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-29.10",
          "val2": "-53.80",
          "chgp": "45.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "11.30",
          "val2": "7.50",
          "chgp": "50.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-12.50",
          "val2": "3.30",
          "chgp": "-478.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-50.30",
          "val2": "-53.00",
          "chgp": "5.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-71.80%",
          "val2": "-152.80%",
          "chgp": "8.10%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

147.40

104.40

41.19%

Operating Profit (PBDIT) excl Other Income

-4.90

-8.10

39.51%

Interest

1.90

5.60

-66.07%

Exceptional Items

5.20

-3.40

252.94%

Consolidate Net Profit

-2.10

-16.10

86.96%

Operating Profit Margin (Excl OI)

-44.20%

-94.90%

5.07%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 41.19% vs 10.24% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 86.96% vs 1.23% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

502.70

393.40

27.78%

Operating Profit (PBDIT) excl Other Income

-29.10

-53.80

45.91%

Interest

11.30

7.50

50.67%

Exceptional Items

-12.50

3.30

-478.79%

Consolidate Net Profit

-50.30

-53.00

5.09%

Operating Profit Margin (Excl OI)

-71.80%

-152.80%

8.10%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 27.78% vs 21.34% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 5.09% vs 21.94% in Dec 2024

All Annual Results

Company CV

About The Oncology Institute, Inc.

The Oncology Institute, Inc.

Pharmaceuticals & Biotechnology

DFP Healthcare Acquisitions Corp. is a blank check company. The Company’s business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It focuses on identifying a target business in the healthcare or healthcare-related industries in the United States and other developed countries. The Company focuses its investment effort across the entire healthcare industry, which encompasses services, therapeutics, devices, diagnostics and animal health.

Company Coordinates

Company Details

780 Third Avenue , NEW YORK NY : 10017

Tel: 1 212 5511600

Registrar Details